Maintenance chemotherapy showed no clear difference in 3‐year PFS compared with maintenance radiotherapy (low certainty).
Maintenance chemotherapy showed no clear difference in 3‐year OS compared with maintenance radiotherapy (low certainty).
Maintenance chemotherapy showed no clear difference in 5‐year OS compared with maintenance radiotherapy (low certainty).
Maintenance chemotherapy showed no clear difference in 10‐year OS compared with maintenance radiotherapy (low certainty).
Maintenance chemotherapy showed no clear difference in 3‐year PFS compared with observation (moderate certainty).
Maintenance chemotherapy showed no clear difference in 3‐year OS compared with observation (moderate certainty).
Maintenance chemotherapy showed no clear difference in 5‐year OS compared with observation (moderate certainty).
Maintenance chemotherapy showed no clear difference in 10‐year OS compared with observation (moderate certainty).
Platin‐based maintenance chemotherapy showed no clear difference in 3‐year OS compared with observation (moderate certainty).
Platin‐based maintenance chemotherapy showed no clear difference in 5‐year OS compared with observation (moderate certainty).
Platin‐based maintenance chemotherapy showed no clear difference in 10‐year OS compared with observation (moderate certainty).
Platin‐based maintenance chemotherapy showed no clear difference in 3‐year PFS compared with observation (moderate certainty).
Doxorubicin‐based maintenance chemotherapy showed no clear difference in 3‐year OS compared with observation (moderate certainty).
Doxorubicin‐based maintenance chemotherapy showed no clear difference in 5‐year OS compared with observation (moderate certainty).
GnRH agonist plus chemotherapy may leads to higher menstruation recovery or maintenance: compared with chemotherapy alone (low certainty).
It is very uncertain whether gnRH agonist‐antagonist cotreatment plus chemotherapy changes menstruation recovery or maintenance: compared with chemotherapy alone (very low certainty).
Chemotherapy with TKI followed by TKI maintenance probably leads to higher any adverse event grade ≥ 3 compared with chemotherapy alone (moderate certainty).
Chemotherapy with TKI followed by TKI maintenance may leads to higher hypertension grade ≥ 3 compared with chemotherapy alone (low certainty).
The review found no eligible studies for this question.
Chemotherapy with TKI followed by TKI maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (low certainty).